Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Non-muscle-invasive bladder cancer

- PMLiVE

J&J agrees $700m settlement with US states to resolve talcum powder claims

The company has ended global sales of the affected products in favour of cornstarch versions

- PMLiVE

Ipsen and Marengo expand oncology research partnership in deal worth $1.2bn

The new agreement centres around Marengo’s TriSTAR T-cell engager platform

- PMLiVE

Sanofi shares positive late-stage results for Sarclisa in newly diagnosed multiple myeloma

More than 180,000 new cases of the haematological malignancy are diagnosed globally every year

- PMLiVE

ICR researchers identify new treatment pathway for rare set of childhood brain tumours

Gliomatosis cerebri is a highly aggressive glioma that affects 100 people in the US every year

- PMLiVE

Bristol Myers Squibb’s Breyanzi receives FDA approval for mantle cell lymphoma

The rare form of non-Hodgkin lymphoma accounts for around 3% of all NHL cases

- PMLiVE

ICR’s cancer cell study could offer longer-lasting protection for breast cancer patients

The condition affects over 55,000 people in the UK every year

- PMLiVE

The Power of Patient Insights to Improve Cancer Care

Two global patient advocacy groups—The Lymphoma Coalition and Lung Cancer Europe— are compiling data from their communities on the real-world experience of living with cancer. What the data reveals sometimes...

Medscape Education Global

- PMLiVE

J&J to acquire Numab’s Yellow Jersey Therapeutics in deal worth $1.25bn

The company will expand its immunology portfolio by gaining global rights to YJT’s NM26 in atopic dermatitis

- PMLiVE

Eli Lilly and Aktis enter $1bn partnership to develop anticancer radiopharmaceuticals

Lilly will gain rights to develop Aktis’ lead programme targeting a tumour-associated antigen

- PMLiVE

Johnson & Johnson shares positive phase 3 results for Tremfya versus Stelara in Crohn’s disease

The GALAXI programme comprises three trials evaluating the IL-23 inhibitor in the IBD condition

- PMLiVE

AstraZeneca unveils plans to deliver $80bn in total revenue by 2030

The company expects to launch 20 new medicines by the end of the decade

- PMLiVE

Johnson & Johnson to expand dermatology portfolio with $850m Proteologix acquisition

The company will gain access to two treatments for atopic dermatitis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links